With its recent acquisition of Psilocin Pharma Corp, Revive Therapeutics (CSE: RVV) is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, RVV is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.

RVV has finalized the prototypes and is preparing to scale for manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines.

There are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options.

The drug delivery technology aims to deliver both synthetic and natural extract of psilocybin in a potential number of ways such as orally dissolvable thin films, topical gels, creams or ointments, oral or transdermal patches, oral dosages and foams.

RVV’s delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material with a chitosan material. The tannin material is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties. The chitosan material is derived from a crustacean group having blood-clotting and antimicrobial properties. The delivery technology also has sustained release potential and may allow combining multiple extracts from mushrooms into one formulation.

RVV has entered into a Clinical Trial Agreement (CTA), dated August 28, 2020, with the Board of Regents of the University of Wisconsin System (UWS) to conduct a clinical study entitled, “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.

Under the CTA’s terms, RVV has an exclusive option to obtain an exclusive, worldwide, royalty-bearing commercialization license to all rights, title and interest that UWS may have or obtain in any invention that results from the clinical study.

Christopher R. Nicholas, Ph.D., Assistant Professor at the University of Wisconsin School of Medicine and Public Health, and clinical psychologist at the school’s Program for Research Outreach Therapeutics and Education in the Addictions (PROTEA) in the Department of Family Medicine and Community Health, will serve as principal investigator for this initial safety study. The study will be conducted at the University of Wisconsin Schools of Medicine and Public Health and Pharmacy, which hold a Wisconsin special authorization and Drug Enforcement Administration license to perform clinical research with psilocybin.

This room is designed to be a comfortable and safe space for patients to test innovative treatments, such as psilocybin and MDMA, for mental health challenges.

Members of the PROTEA team previously conducted research on the pharmacokinetics of high-dose psilocybin and are also currently investigating psilocybin as a treatment for opioid use disorder.

Past performance is not an indicator of future returns. Psychstocks is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The parent company of Psychstocks has been compensated by RVV USD$30,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.